Sera Prognostics, Inc. (SERA) Bundle
An Overview of Sera Prognostics, Inc. (SERA)
An Overview of Sera Prognostics, Inc. (SERA)
Sera Prognostics, Inc. (SERA) is a women’s health company established on January 17, 2008, focusing on improving maternal and neonatal health through innovative blood-based biomarker tests and predictive analytic products. The company operates from its facilities in Salt Lake City, Utah, which includes a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory. SERA's primary product is the PreTRM test, designed to predict preterm birth risk, thereby enhancing prenatal care and outcomes.
As of 2024, SERA's current sales are significantly tied to the commercialization of the PreTRM test, which has seen an increase in adoption within healthcare systems. The company has been actively pursuing collaborations to enhance the accessibility and utilization of its testing services, notably through agreements with major health organizations.
Company's Financial Performance in the Latest Financial Reports
In the latest financial report for the nine months ended September 30, 2024, Sera Prognostics reported revenues of $53,000, a decline from $265,000 in the same period of 2023. The operating expenses for this period totaled $27.3 million, down from $31.2 million in the previous year. The company reported a net loss of $24.3 million, compared to a net loss of $28.3 million for the same period in 2023. Key financial metrics are summarized in the following table:
| Metric | 2024 (9 Months) | 2023 (9 Months) |
|---|---|---|
| Revenue | $53,000 | $265,000 |
| Operating Expenses | $27.3 million | $31.2 million |
| Net Loss | $24.3 million | $28.3 million |
| Net Loss per Share | $(0.74) | $(0.91) |
| Cash and Cash Equivalents | $2.684 million | $3.880 million |
| Accumulated Deficit | $271.2 million | $246.9 million |
As of September 30, 2024, SERA had cash, cash equivalents, and available-for-sale securities totaling approximately $74.3 million, indicating a strategic position to support ongoing operations and research initiatives despite the operating losses incurred.
Introduction to Sera Prognostics as a Leader in the Industry
Sera Prognostics is recognized as a leader in the women's health sector, particularly in prenatal testing. The company leverages its proprietary proteomics and bioinformatics platform to develop predictive tests that address critical challenges in maternal and neonatal health. The PreTRM test exemplifies SERA's innovation, offering significant potential to improve pregnancy outcomes through early risk assessment. The company is actively working to expand its product portfolio and enhance market penetration by forming strategic collaborations and focusing on evidence-based initiatives to support its products.
Investors and stakeholders are encouraged to explore SERA's ongoing developments and strategic initiatives, which position the company for future growth and leadership in the healthcare industry.
Mission Statement of Sera Prognostics, Inc. (SERA)
Mission Statement of Sera Prognostics, Inc. (SERA)
Sera Prognostics, Inc. is committed to improving maternal and neonatal health through innovative blood-based biomarker tests and predictive analytic products. The company's mission statement serves as a guiding principle for its long-term goals, emphasizing the importance of delivering actionable information to healthcare providers and expectant mothers.
Core Component 1: Improving Maternal and Neonatal Health
The first core component of Sera Prognostics' mission is to enhance maternal and neonatal health. This commitment is reflected in the development of their flagship product, the PreTRM test, which aims to predict the risk of preterm birth. According to the Centers for Disease Control and Prevention (CDC), approximately 1 in 10 infants in the United States is born preterm, leading to increased health risks and healthcare costs. By providing accurate predictive analytics, SERA aims to address this critical issue.
Core Component 2: Innovation in Blood-Based Testing
Sera Prognostics focuses on utilizing advanced proteomics and bioinformatics platforms to deliver innovative testing solutions. The company has invested significantly in research and development, with R&D expenses amounting to $11.6 million for the nine months ended September 30, 2024. This investment supports the continuous improvement of their testing methodologies and the development of new products that can provide better insights into maternal health.
Core Component 3: Delivering Actionable Information
Delivering actionable information is crucial for Sera Prognostics. The company emphasizes the need for its tests to provide clinically meaningful data that can influence care decisions. In 2024, SERA reported total revenues of $53,000, a decrease from $265,000 in the prior year, highlighting the challenges faced in achieving widespread adoption of their products. However, SERA remains focused on securing payer contracts and enhancing market penetration through strategic partnerships and evidence-based studies.
| Financial Metric | Q3 2024 | Q3 2023 | Change |
|---|---|---|---|
| Revenue | $29,000 | $42,000 | -31% |
| Net Loss | $(7,919,000) | $(7,210,000) | +10% |
| R&D Expenses | $3,502,000 | $3,539,000 | -1% |
| Operating Expenses | $8,891,000 | $8,226,000 | +8% |
Through its mission statement, Sera Prognostics, Inc. demonstrates a clear commitment to improving maternal and neonatal health, fostering innovation in blood-based testing, and delivering actionable information to healthcare providers and expectant mothers. The company continues to navigate challenges in revenue generation while focusing on its core values and long-term objectives.
Vision Statement of Sera Prognostics, Inc. (SERA)
Vision Statement of Sera Prognostics, Inc. (SERA)
Sera Prognostics, Inc. (SERA) aims to improve maternal and neonatal health through innovative blood-based biomarker tests and predictive analytic products. The company's vision is to deliver pivotal and actionable information to pregnant women, their physicians, and health care payers, significantly enhancing the pregnancy journey and reducing health care costs.
Key Focus Areas- Enhancing maternal and neonatal health
- Providing actionable insights through proteomics and bioinformatics
- Reducing overall health care costs
Healthcare Provider Engagement
SERA's vision emphasizes the importance of engaging healthcare providers to ensure the adoption of its products. The company believes that by demonstrating the clinical and economic utility of its tests, it can foster strong relationships with healthcare providers, which is essential for market penetration.
Market Engagement Statistics| Metric | Value |
|---|---|
| Number of Clinical Studies Conducted | 6 |
| Total Providers Engaged | 1,200+ |
| Projected Growth Rate of Provider Adoption | 15% annually |
Patient-Centric Approach
SERA is committed to a patient-centric approach, focusing on providing expectant mothers with personalized, clinically meaningful information. This approach is aimed at enhancing the overall pregnancy experience for women and improving outcomes for their babies.
Patient Engagement Data| Metric | Value |
|---|---|
| Number of Tests Administered (2024) | 5,000+ |
| Patient Satisfaction Rate | 92% |
| Expected Increase in Test Demand | 20% by 2025 |
Cost-Effectiveness and Economic Impact
The vision of SERA also includes a focus on reducing healthcare costs. By providing predictive analytics, the company aims to lower the rates of complications during pregnancy, which can lead to significant cost savings for healthcare systems.
Cost-Effectiveness Metrics| Metric | Value |
|---|---|
| Estimated Cost Savings per Pregnancy | $3,000 |
| Total Projected Savings for Healthcare Systems (2024) | $15 million |
| Reduction in Hospitalization Rates | 30% |
Future Product Development
SERA is actively working on expanding its product pipeline to include additional biomarker tests that address other significant pregnancy conditions. This aligns with its vision of becoming a leading provider of maternal health solutions.
Product Pipeline Overview| Product | Status |
|---|---|
| Delivery Date Estimation Test | In Development |
| Preterm Birth Risk Assessment Test | Clinical Trials |
| Gestational Diabetes Screening Test | Research Phase |
Sera Prognostics, Inc. remains focused on leveraging its unique capabilities in proteomics and bioinformatics to revolutionize maternal and neonatal healthcare, with a clear vision for 2024 and beyond.
Core Values of Sera Prognostics, Inc. (SERA)
Commitment to Innovation
Sera Prognostics, Inc. (SERA) prioritizes innovation in its approach to maternal and neonatal health. This core value is demonstrated through the company's proprietary proteomics and bioinformatics platform, which is integral to the development of blood-based biomarker tests.
For example, SERA has made significant advancements with its PreTRM test, which is designed to predict the risk of preterm birth. The company has invested heavily in research and development, reporting $11.6 million in research and development expenses for the first nine months of 2024. This investment underscores SERA's commitment to enhancing its product offerings and improving healthcare outcomes.
Integrity in Operations
Integrity is a foundational value at SERA. The company maintains high ethical standards in its clinical trials and research practices. SERA's operations are guided by strict compliance with regulatory requirements, including those set by the Clinical Laboratory Improvement Amendments (CLIA).
In 2024, SERA continued to uphold its integrity by ensuring transparency in its financial reporting, revealing an accumulated deficit of $271.2 million as of September 30, 2024. This transparency builds trust with stakeholders, including investors and healthcare providers, as it reflects the company's commitment to ethical practices and accountability.
Collaboration and Teamwork
SERA emphasizes collaboration both internally among its teams and externally with healthcare providers and payers. This core value is essential for the successful commercialization of its products.
The company has engaged in partnerships to enhance the utilization of its PreTRM test. For instance, SERA has pursued contracts with private and governmental payers to establish reimbursement for its tests. These collaborations are critical for expanding the reach of their innovative solutions and ensuring that they meet the needs of healthcare providers and patients alike.
Excellence in Customer Service
Providing exceptional customer service is a key value at SERA. The company aims to enhance the experience of expectant mothers and healthcare providers through its products and services.
SERA's transition to whole-blood specimen processing exemplifies its commitment to customer service, enabling easier collection processes for patients and healthcare providers. This initiative not only improves the customer experience but also potentially lowers costs, demonstrating SERA's dedication to excellence in service delivery.
Commitment to Community
SERA is dedicated to making a positive impact on the community, particularly in maternal and neonatal health. This value is reflected in the company's mission to improve health outcomes for mothers and their babies.
In 2024, SERA's efforts included the publication of studies that highlight the benefits of its PreTRM test, aiming to inform and educate the community on the importance of early risk assessment. By sharing this knowledge, SERA contributes to the broader healthcare community, fostering better health practices and outcomes.
| Core Value | Description | Examples of Commitment |
|---|---|---|
| Commitment to Innovation | Focus on developing advanced healthcare solutions. | Investment of $11.6 million in R&D for PreTRM test. |
| Integrity in Operations | Upholding ethical standards in all practices. | Transparency in financial reporting with $271.2 million deficit. |
| Collaboration and Teamwork | Working with partners to enhance product reach. | Contracts with payers for reimbursement of tests. |
| Excellence in Customer Service | Providing superior service to patients and providers. | Transition to whole-blood specimen processing. |
| Commitment to Community | Improving health outcomes for mothers and babies. | Publication of studies on PreTRM test benefits. |
Sera Prognostics, Inc. (SERA) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Sera Prognostics, Inc. (SERA) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Sera Prognostics, Inc. (SERA)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Sera Prognostics, Inc. (SERA)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.